ezogabine (Potiga, retigabine)
Jump to navigation
Jump to search
Introduction
FDA approved June 2011
Indications
- adjunctive treatment of partial seizures
Dosage
- start: 100 mg TID for 1 week
- titrate at weekly intervals; increase by <= 150 mg/day
- maintenance: 200-400 mg TID*
- taper over 3 weeks when discontinuing[7]
* 400 mg TID of limited benefit with increased incidence of adverse effects relative to 300 mg TID[7]
Monitor
- baseline eye exam & periodic eye exams
- visual acuity testing
- dilated fundus photography
- in some cases
Adverse effects
- sedation
- dizziness
- fatigue
- urinary retention
- memory impairment
- confusion
- psychosis
- hallucinations[6]
- may increase risk of suicidal ideation
- diplopia
- blue skin discoloration[3]
- retinal pigment disorder
- potential vision loss[4][5]
- QT prolongation
Laboratory
Mechanism of action
- facilitates opening of potassium channels
More general terms
References
- ↑ FDA NEWS RELEASE: June 13, 2011 FDA approves Potiga to treat seizures in adults http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm258834.htm
- ↑ French JA et al. on behalf of the RESTORE 1/Study 301 Investigators. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 2011 Mar 30 http://www.neurology.org/content/76/18/1555
- ↑ 3.0 3.1 3.2 FDA MedWatch, April 26, 2013 Potiga (Ezogabine): Drug Safety Communication - Linked To Retinal Abnormalities And Blue Skin Discoloration. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm349847.htm
- ↑ 4.0 4.1 FDA Drug Safety Communication: FDA approves label changes for anti-seizure drug Potiga (ezogabine) describing risk of retinal abnormalities, potential vision loss, and skin discoloration. October 31, 2013 http://www.fda.gov/Drugs/DrugSafety/ucm372774.htm
- ↑ 5.0 5.1 FDA Drug Safety Communication. June 16, 2015 Potiga (ezogabine): Drug Safety Communication - FDA Determines 2013 Labeling Adequate to Manage Risks of Retinal Abnormalities, Potential Vision Loss, and Skin Discoloration. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm451181.htm
- ↑ 6.0 6.1 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
- ↑ 7.0 7.1 7.2 Ezogabin (Potiga) tablets prescribing information https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Potiga/pdf/POTIGA-PI-MG.PDF